Between the Biotech Waves cover image

Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking

Between the Biotech Waves

00:00

Are the M&A Financings of the Past a Good Idea?

There's 650 public companies and 250 are in a distressed cash runway position approaching 12 months of cash, there's 400 companies that actually have healthy balance sheets. A large number of them had positive events and were able to raise substantial capital off of those events. And so there certainly is, you know, at the end of the day, financings that are being done with,. you know, substantial warrant coverage and a fair amount of pollution. But I would say what encouraged me as we had into 2023 is the creativity that's brought to bear to try and get companies in a healthier situation than they currently are.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app